Israel - Ibrani - Ministry of Health

abic marketing ltd, israel - treprostinil as sodium - תמיסה לאינפוזיה - treprostinil as sodium 2.5 mg/ml - treprostinil

Israel - Ibrani - Ministry of Health

abic marketing ltd, israel - treprostinil as sodium - תמיסה לאינפוזיה - treprostinil as sodium 5 mg/ml - treprostinil

Israel - Ibrani - Ministry of Health

abic marketing ltd, israel - ambrisentan - טבליות מצופות פילם - ambrisentan 10 mg - ambrisentan

Israel - Ibrani - Ministry of Health

abic marketing ltd, israel - ambrisentan - טבליות מצופות פילם - ambrisentan 5 mg - ambrisentan

Israel - Ibrani - Ministry of Health

padagis israel pharmaceuticals ltd, israel - mebeverine hydrochloride - טבליה - mebeverine hydrochloride 135 mg - mebeverine - mebeverine - irritable bowel syndrome and conditions included in this group such as: chronic irritable colon, gastro- intestinal spasm secondary to organic diseases

Israel - Ibrani - Ministry of Health

padagis israel agencies ltd, israel - granisetron as hydrochloride - טבליה - granisetron as hydrochloride 1 mg - granisetron - granisetron - prevention of nausea and vomiting induced by cytostatic therapy.

Israel - Ibrani - Ministry of Health

padagis israel pharmaceuticals ltd, israel - glipizide - טבליה - glipizide 5 mg - glipizide - glipizide - is indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with diabetes mellitus type ii

Israel - Ibrani - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor

Israel - Ibrani - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal

Israel - Ibrani - Ministry of Health

padagis israel pharmaceuticals ltd, israel - clotrimazole - קרם - clotrimazole 1 %w/w - clotrimazole - clotrimazole - skin infections caused by dermatophytes or candida species.